A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms

Eur J Dermatol. 2017 Apr 1;27(2):184-185. doi: 10.1684/ejd.2016.2923.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • CTLA-4 Antigen / genetics*
  • Diabetes Mellitus, Type 1 / chemically induced*
  • Diabetes Mellitus, Type 1 / genetics
  • Female
  • HLA Antigens / genetics*
  • Humans
  • Melanoma / drug therapy
  • Melanoma / secondary
  • Middle Aged
  • Nivolumab
  • Organ Size / genetics
  • Pancreas / pathology*
  • Polymorphism, Genetic
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / pathology

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • CTLA-4 Antigen
  • HLA Antigens
  • Nivolumab